A detailed history of China Universal Asset Management Co., Ltd. transactions in Ardelyx, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 45,280 shares of ARDX stock, worth $206,929. This represents 0.03% of its overall portfolio holdings.

Number of Shares
45,280
Previous 27,488 64.73%
Holding current value
$206,929
Previous $203,000 53.2%
% of portfolio
0.03%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$5.28 - $7.57 $93,941 - $134,685
17,792 Added 64.73%
45,280 $311,000
Q2 2024

Jul 19, 2024

SELL
$5.89 - $9.31 $101,696 - $160,746
-17,266 Reduced 38.58%
27,488 $203,000
Q1 2024

Apr 29, 2024

BUY
$6.05 - $9.74 $108,313 - $174,375
17,903 Added 66.68%
44,754 $327,000
Q4 2023

May 21, 2024

SELL
$3.29 - $6.64 $58,900 - $118,875
-17,903 Reduced 40.0%
26,851 $166,000
Q4 2023

Jan 23, 2024

BUY
$3.29 - $6.64 $69,942 - $141,159
21,259 Added 380.17%
26,851 $166,000
Q3 2023

May 21, 2024

BUY
$3.3 - $4.83 $9,177 - $13,432
2,781 Added 98.93%
5,592 $22,000
Q3 2023

Oct 30, 2023

BUY
$3.3 - $4.83 $9,177 - $13,432
2,781 Added 98.93%
5,592 $23,000
Q2 2023

May 21, 2024

BUY
$3.23 - $4.95 $390 - $598
121 Added 4.5%
2,811 $9,000
Q2 2023

Jul 27, 2023

BUY
$3.23 - $4.95 $390 - $598
121 Added 4.5%
2,811 $10,000
Q1 2023

May 21, 2024

BUY
$2.68 - $4.79 $2,106 - $3,764
786 Added 41.28%
2,690 $12,000
Q1 2023

Apr 27, 2023

BUY
$2.68 - $4.79 $2,106 - $3,764
786 Added 41.28%
2,690 $13,000
Q4 2022

May 21, 2024

SELL
$1.22 - $2.85 $52,277 - $122,122
-42,850 Reduced 95.75%
1,904 $5,000
Q4 2022

Jan 31, 2023

BUY
$1.22 - $2.85 $2,322 - $5,426
1,904 New
1,904 $5,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $707M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.